×
About 1,320 results

ALLMedicine™ Hyperoxaluria Center

Research & Reviews  445 results

Improving Treatment Options for Primary Hyperoxaluria.
https://doi.org/10.1007/s40265-022-01735-x 10.1056/NEJMra1301564 10.1038/nrneph.2012.113 10.1016/S0140-6736(86)90584-2 10.1093/hmg/8.11.2063 10.1016/j.ajhg.2010.07.023 10.2215/CJN.02760311 10.1007/s10545-017-0045-3 10.1016/j.kint.2019.08.018 10.1093/ndt/gfab027 10.1016/j.kint.2021.03.031 10.1053/j.ajkd.2021.05.016 10.1038/ki.2014.222 10.1007/s11255-018-1939-1 10.1007/s00240-010-0290-5 10.1172/JCI63679 10.1038/ki.2013.207 10.1046/j.1523-1755.1999.00546.x 10.1159/000186708 10.1016/j.ajo.2019.04.036 10.1007/s00467-017-3731-3 10.21009/jimd.v15i1.9108 10.1007/s00467-018-3967-6 10.1016/j.ijsu.2016.10.039 10.2215/CJN.02810315 10.3389/fped.2018.00098 10.1080/14728214.2018.1552940 10.1007/BF00864405 10.1038/ki.1990.265 10.1111/j.1600-6143.2010.03271.x 10.1038/sj.ki.5001806 10.1007/s004670050145 10.1177/089686089401400117 10.1093/ndt/gfs078 10.1007/s00467-021-05043-6 10.1034/j.1399-3046.2000.00107.x 10.1097/TP.0b013e3181a27939 10.1046/j.1523-1755.1999.00619.x 10.1053/jlts.2001.28741 10.1007/s00467-003-1234-x 10.1111/ajt.14418 10.1111/ajt.15829 10.7326/0003-4819-55-1-70 10.1056/NEJM199412083312304 10.1136/adc.42.225.505 10.3109/03009737809179114 10.3109/00365598009181192 10.1136/bmj.282.6282.2097-a 10.1016/S0140-6736(86)90221-7 10.1007/BF00297371 10.1016/S0272-6386(12)80315-5 10.1681/ASN.V341018 10.1093/ndt/14.2.301 10.1074/jbc.M109.038372 10.1016/j.bbadis.2012.03.004 10.1093/hmg/ddv276 10.1074/jbc.M112.432617 10.1371/journal.pbio.1001309 10.1074/jbc.M803525200 10.1016/j.ymgme.2011.09.033 10.1093/ndt/18.2.273 10.1111/j.1523-1755.2005.00054.x 10.1007/s00240-005-0493-3 10.1159/000369310 10.1159/000108104 10.2215/CJN.06820613 10.1007/BF01957682 10.1111/j.1523-1755.2005.00267.x 10.1159/000085411 10.1159/000085407 10.1007/BF00849265 10.1016/j.kint.2021.08.015 10.1681/ASN.2016030338 10.1056/NEJMoa2021712 10.1038/mt.2016.4 10.1007/s40265-020-01463-0 10.2215/CJN.14730920 10.7554/eLife.54363 10.1007/s00467-021-05393-1 10.3389/fped.2021.791616 10.1111/ajt.16762 10.1016/j.jacc.2021.06.039 10.1177/20543581211058931 10.1016/j.kint.2021.10.022 10.1016/j.ekir.2021.01.029 10.1016/j.urology.2021.03.014 10.1097/MNH.0000000000000790 10.1016/j.ejmech.2022.114396 10.1021/acsmedchemlett.1c00196 10.1038/mt.2015.224 10.1021/acs.jmedchem.8b00399 10.1172/JCI99822 10.1097/MNH.0000000000000621 10.1093/ckj/sfaa068 10.1007/s00467-020-04585-5 10.1038/s41585-021-00543-4 10.1016/j.omtm.2022.03.006 10.1007/s00240-004-0445-3 10.1038/sj.ki.5000162 10.1152/ajpgi.00434.2010 10.1159/000151395 10.1093/ndt/gfaa135 10.1038/sj.ki.5001707 10.1007/s00467-016-3553-8 10.1172/JCI43122 10.1016/j.scr.2019.101467 10.1093/ndt/gfr776 10.1097/TP.0b013e31816de49e 10.1038/mt.2010.270 10.3389/fimmu.2018.01160 10.1016/j.omtm.2017.06.007 10.1016/bs.apcsb.2018.09.003 10.1007/s00109-018-1651-8 10.1073/pnas.1408401111 10.1016/j.bbagen.2016.08.006 10.1038/srep34060
Drugs Hoppe B, Martin-Higueras C

Jul 3rd, 2022 - The primary hyperoxalurias are three rare inborn errors of the glyoxylate metabolism in the liver, which lead to massively increased endogenous oxalate production, thus elevating urinary oxalate excretion and, based on that, recurrent urolithiasis...

Long Term Extension Study in Patients With Primary Hyperoxaluria
https://clinicaltrials.gov/ct2/show/NCT04042402

Jun 27th, 2022 - The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients ...

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
https://clinicaltrials.gov/ct2/show/NCT03847909

Jun 22nd, 2022 - The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)

Analysis and Characterization of Lactobacillus paragasseri and Lacticaseibacillus parac...
https://doi.org/10.1007/s12602-022-09958-w 10.1053/J.AJKD.2021.07.018 10.1038/S41581-020-00392-1 10.1016/J.POP.2008.01.005 10.1155/2014/648059 10.1016/J.UROLOGY.2013.08.002 10.1046/J.1523-1755.2003.00807.X 10.1016/J.UROLOGY.2008.10.035 10.1016/J.UROLOGY.2012.02.052 10.1038/srep34712 10.1136/GUTJNL-2017-315734 10.1016/j.kint.2019.02.012 10.1186/s40168-017-0316-0 10.1097/MCG.0000000000000228 10.1371/journal.pone.0222393 10.1093/CID/CIV072 10.1038/s41575-019-0173-3 10.1093/ADVANCES/NMY063 10.1136/GUT.2008.167270 10.1136/BMJOPEN-2017-017995 10.1038/s41598-020-68440-1 10.3390/CELLS11020284 10.1111/j.1365-2672.2007.03388.x 10.1016/j.vetmic.2008.10.005 10.1046/j.1523-1755.2001.0600031097.x 10.1371/journal.pcbi.1005595 10.1093/bioinformatics/btv171 10.1093/nar/gkw569 10.1371/JOURNAL.PONE.0077302 10.1093/bioinformatics/btv681 10.1038/s41467-019-10210-3 10.1046/j.1365-2672.2003.01850.x 10.1002/fsn3.1025 10.1016/j.yclnex.2018.10.001 10.1007/S12602-018-9387-X 10.1038/NMICROBIOL.2016.77 10.1038/nmeth.2019 10.1016/0009-8981(72)90167-2 10.1016/j.jff.2015.05.011 10.1016/J.YGENO.2018.05.022 10.3389/fgene.2019.00812 10.1016/j.cellsig.2017.07.009 10.1016/J.AOAS.2016.03.001 10.3389/FIMMU.2021.616713/BIBTEX 10.1111/J.1365-2672.2012.05390.X 10.1007/S00240-006-0054-4 10.1681/ASN.2007101058 10.1128/AEM.00216-16 10.1093/JN/91.4.496 10.1038/ki.2010.310 10.1111/J.1442-2042.2005.01038.X 10.1046/j.1523-1755.1999.00281.x 10.1016/S0378-1097(03)00864-4 10.1159/000504417 10.1111/1750-3841.12344 10.1007/s00240-014-0728-2 10.1016/S0065-2164(10)72003-7 10.3389/fmicb.2015.00058 10.1128/MMBR.00076-15 10.1177/0394632015590948 10.1016/J.LWT.2019.02.002 10.1007/S00284-019-01769-7 10.1111/J.1745-4565.2009.00201.X 10.1016/J.FOODRES.2020.109571 10.3389/FMICB.2013.00202/BIBTEX 10.1016/J.ANAEROBE.2015.03.004 10.1128/AEM.70.12.7200-7209.2004 10.1016/J.IJFOODMICRO.2005.03.008 10.1159/000342079 10.1016/J.RESMIC.2005.09.002 10.1111/J.1574-6968.2006.00250.X 10.1111/J.1472-765X.2007.02212.X 10.3389/FMICB.2019.00789/BIBTEX 10.4103/0971-5916.90992 10.1111/JAM.13757 10.1038/NRNEPH.2016.101 10.1016/S0140-6736(06)68071-9 10.1016/j.micres.2018.06.009 10.3109/15563650903344793 10.1080/07315724.1982.10718985 10.2215/CJN.07060714 10.5527/wjn.v3.i4.256 10.1111/j.1523-1755.2005.00520.x
Probiotics and Antimicrobial Proteins; Mehra Y, Rajesh NG et. al.

Jun 15th, 2022 - In the present study, we characterized the probiotic properties of two commercially available bacterial strains, Lactobacillus paragasseri UBLG-36 and Lacticaseibacillus paracasei UBLPC-87, and evaluated their ability to degrade oxalate in vitro a...

Genetic assessment in primary hyperoxaluria: why it matters.
https://doi.org/10.1007/s00467-022-05613-2 10.1038/ki.2014.222 10.1681/ASN.2014070698 10.1016/j.bone.2015.07.010 10.1253/circj.CJ-10-0107 10.1002/mus.24495 10.1056/NEJMoa2021712 10.1007/s00240-016-0860-2 10.1056/NEJMra1301564 10.1016/0014-5793(86)80563-4 10.1016/0888-7543(91)90481-S 10.1016/j.bbadis.2012.03.004 10.1016/S0272-6386(12)80624-X 10.1016/j.ajo.2019.04.036 10.1023/A:1005326510239 10.1016/S0009-8981(97)00165-4 10.1017/S1462399404007203 10.1002/humu.21021 10.1111/j.1523-1755.2004.00842.x 10.1038/ki.2009.435 10.1007/s40620-016-0287-4 10.1073/pnas.88.23.10900 10.1089/gtmb.2015.0136 10.1073/pnas.1131968100 10.1007/s00240-020-01201-x 10.1007/s00240-017-0996-8 10.1007/s11596-018-1941-y 10.1093/ndt/gfs078 10.2215/CJN.06820613 10.1016/j.bbadis.2013.04.010 10.1074/jbc.M808965200 10.1016/j.clinbiochem.2013.11.021 10.1371/journal.pone.0071963 10.1016/j.biochi.2016.10.001 10.1111/j.1523-1755.2005.00267.x 10.1111/j.1523-1755.2004.00796.x 10.1016/j.ekir.2021.11.006 10.1053/j.ajkd.2020.07.017 10.1681/ASN.2021060729 10.1016/j.bbapap.2015.07.002 10.1016/j.ymgme.2020.07.012 10.1016/j.bbadis.2013.09.002 10.1038/sj.ki.5001758 10.1016/j.bbapap.2010.12.005 10.1016/j.ekir.2020.04.004 10.1093/hmg/ddv276 10.1056/NEJM196802012780502 10.1016/j.kint.2019.08.018 10.1016/j.ajhg.2010.07.023 10.1007/s00109-012-0930-z 10.1016/j.kint.2021.03.031 10.1093/ndt/gfab027 10.1093/ndt/gfs039 10.1038/ejhg.2012.139 10.1007/s00467-019-04279-7 10.1159/000086357 10.1016/S0272-6386(97)90006-8 10.1038/ng1762 10.1152/ajpgi.00481.2005 10.1007/s00467-021-05393-1 10.1093/hropen/hoaa021 10.1007/s00467-002-0858-6 10.1016/j.kint.2021.08.015 10.1515/medgen-2021-2052
Pediatric Nephrology (Berlin, Germany); Mandrile G, Beck B et. al.

Jun 14th, 2022 - Accurate diagnosis of primary hyperoxaluria (PH) has important therapeutic consequences. Since biochemical assessment can be unreliable, genetic testing is a crucial diagnostic tool for patients with PH to define the disease type. Patients with PH...

see more →

Guidelines  1 results

Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and ...
https://doi.org/10.1093/ndt/gfs078
Nephrology, Dialysis, Transplantation : Official Publicat... Cochat P, Hulton SA et. al.

May 2nd, 2012 - Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  59 results

Long Term Extension Study in Patients With Primary Hyperoxaluria
https://clinicaltrials.gov/ct2/show/NCT04042402

Jun 27th, 2022 - The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients ...

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
https://clinicaltrials.gov/ct2/show/NCT03847909

Jun 22nd, 2022 - The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
https://clinicaltrials.gov/ct2/show/NCT03847090

Jun 10th, 2022 - This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study. This study is designed to determine the short- and long-term efficacy of reloxaliase in terms of reducing urinary oxalate excretion and clinical benefits ...

Renal Metabolism of Glycolate to Oxalate
https://clinicaltrials.gov/ct2/show/NCT04437225

Jun 3rd, 2022 - It is known that glycolate, an intermediary molecule in normal metabolism, can be converted into oxalate. The origin of urinary oxalate is of interest as calcium oxalate is a main component of kidney stones. In the rare disease primary hyperoxalur...

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
https://clinicaltrials.gov/ct2/show/NCT03905694

Jun 3rd, 2022 - The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).

see more →

News  18 results

Lumasiran Effects in Rare Disease Seen Despite Kidney Status
https://www.medscape.com/viewarticle/962578

Nov 9th, 2021 - Lumasiran has shown benefit in reducing plasma oxalate in patients with primary hyperoxaluria type 1 (PH1) and severely impaired kidney function, according to new research.  Lumasiran (Oxlumo, Alnylam Pharmaceuticals), an RNA interference (RNAi) t...

Future 'Exceedingly Bright' for Kidney Stone Prevention
https://www.medscape.com/viewarticle/958630

Sep 13th, 2021 - Gene therapy, new therapeutics currently in clinical trials, and a promising dietary supplement are feeding the optimism of kidney stone expert Glenn Preminger, MD. Glenn Preminger "The future of kidney stones looks exceedingly bright," said Premi...

Fast Five Quiz: Primary Hyperoxaluria Type 1 Management
https://reference.medscape.com/viewarticle/944415

Mar 1st, 2021 - Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disease that is caused by a functional defect of alanine:glyoxylate aminotransferase catalysis, resulting in the overproduction of oxalate. The clinical impact of PH1 can be devastat...

Fast Five Quiz: Primary Hyperoxaluria Type 1 Screening and Diagnosis
https://reference.medscape.com/viewarticle/944411

Mar 1st, 2021 - Primary hyperoxaluria (PH) encompasses a group of rare genetic metabolic disorders that are characterized by the accumulation of oxalate in the kidneys and other organs. PH is categorized as type 1 (PH1), type 2 (PH2) or type 3 (PH3). An estimated...

FDA Clears First Drug to Treat Ultra-Rare Metabolic Disorder
https://www.medscape.com/viewarticle/941520

Nov 24th, 2020 - The US Food and Drug Administration (FDA) has approved lumasiran (Oxlumo, Alnylam Pharmaceuticals) subcutaneous injection to treat children and adults with primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder that causes recurrent ki...

see more →

Patient Education  4 results see all →